ParkinsonCanadaV1, France, Analysis, bibRecord, 000232

Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

Identifieur interne : 000232 ( France/Analysis ); précédent : 000231; suivant : 000233

Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

Auteurs : Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]

Source :

Movement Disorders [ 0885-3185 ] ; 2007-12-15.

RBID : ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1

Descripteurs français

Pascal (Inist)
- Complication, Dyskinésie, Homme, Lévodopa, Maladie de Parkinson, Pathologie du système nerveux, Ropinirole, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Complication, Dyskinesia, Human, Levodopa, Nervous system diseases, Parkinson disease, Parkinson's disease, Ropinirole, Treatment, dopamine agonist, dyskinesia, levodopa, motor complications, ropinirole, treatment, wearing off.

Abstract

In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society

Url:

https://api-v5.istex.fr/document/1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1/fulltext/pdf

DOI: 10.1002/mds.21743

Affiliations:

Links to Exploration step

ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
</author>
<author><name sortKey="Jon Stoessl, A" sort="Jon Stoessl, A" uniqKey="Jon Stoessl A" first="A." last="Jon Stoessl">A. Jon Stoessl</name>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21743</idno>
<idno type="url">https://api-v5.istex.fr/document/1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000867</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000867</idno>
<idno type="wicri:Area/Istex/Curation">000867</idno>
<idno type="wicri:Area/Istex/Checkpoint">000A05</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A05</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Hauser R:ten:year:follow</idno>
<idno type="wicri:Area/Main/Merge">002768</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0146745</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000664</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000646</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000592</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000592</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Hauser R:ten:year:follow</idno>
<idno type="wicri:Area/Main/Merge">002882</idno>
<idno type="wicri:Area/Main/Curation">002525</idno>
<idno type="wicri:Area/Main/Exploration">002525</idno>
<idno type="wicri:Area/France/Extraction">000232</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>University Hospital, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Tel Aviv University Medical School, Ramat Aviv</wicri:regionArea>
<wicri:noRegion>Ramat Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jon Stoessl, A" sort="Jon Stoessl, A" uniqKey="Jon Stoessl A" first="A." last="Jon Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Alabama, Birmingham, Alabama</wicri:regionArea>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>University of Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name>
<affiliation wicri:level="4"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>University of Antwerp, Antwerp</wicri:regionArea>
<orgName type="university">Université d'Anvers</orgName>
<placeName><settlement type="city">Anvers</settlement>
<region>Région flamande</region>
<region type="district" nuts="2">Province d'Anvers</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-12-15">2007-12-15</date>
<biblScope unit="volume">22</biblScope>
<biblScope unit="issue">16</biblScope>
<biblScope unit="page" from="2409">2409</biblScope>
<biblScope unit="page" to="2417">2417</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</idno>
<idno type="DOI">10.1002/mds.21743</idno>
<idno type="ArticleID">MDS21743</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Complication</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Ropinirole</term>
<term>Treatment</term>
<term>dopamine agonist</term>
<term>dyskinesia</term>
<term>levodopa</term>
<term>motor complications</term>
<term>ropinirole</term>
<term>treatment</term>
<term>wearing off</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Complication</term>
<term>Dyskinésie</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Ropinirole</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>Belgique</li>
<li>Canada</li>
<li>France</li>
<li>Israël</li>
<li>États-Unis</li>
</country>
<region><li>Alabama</li>
<li>Floride</li>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Province d'Anvers</li>
<li>Région flamande</li>
<li>Tyrol (Land)</li>
</region>
<settlement><li>Anvers</li>
<li>Innsbruck</li>
<li>Tampa</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université d'Anvers</li>
<li>Université de Floride du Sud</li>
<li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
<name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</region>
</country>
<country name="Israël"><noRegion><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
</noRegion>
</country>
<country name="Canada"><noRegion><name sortKey="Jon Stoessl, A" sort="Jon Stoessl, A" uniqKey="Jon Stoessl A" first="A." last="Jon Stoessl">A. Jon Stoessl</name>
</noRegion>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</country>
<country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</region>
</country>
<country name="Belgique"><region name="Région flamande"><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000232 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000232 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1
   |texte=   Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.